Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Implications of the REDUCE-IT trial outcomes in a real-world population of ischemic heart disease patients
Session:
Posters 2 - Écran 5 - Prevenção
Speaker:
Pedro M. Lopes
Congress:
CPC 2019
Topic:
J. Preventive Cardiology
Theme:
28. Risk Factors and Prevention
Subtheme:
28.4 Lipids
Session Type:
Posters
FP Number:
---
Authors:
Pedro M. Lopes; Carlos Aguiar; Jorge Santos Ferreira; Gustavo Da Rocha Rodrigues; Afonso Félix De Oliveira; Catarina Brízido; Daniel Nascimento Matos; António Miguel Ferreira; Marisa Trabulo; Miguel Mendes
Abstract
<p><strong>Introduction: </strong>Despite intensive statin treatment, some patients remain at high risk of cardiovascular events. The REDUCE-IT trial showed that a high dose of the omega-3 ethyl eicosapentaenoic acid (EPA) in addition to statin treatment significantly reduced cardiovascular death and events during a mean follow-up period of 4.9 years, in a high cardiovascular risk population with elevated triglyceride (TG) levels.</p> <p><strong>Aim:</strong> To assess the proportion of patients in a real-world population with established coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) who might benefit from this therapy.</p> <p><strong>Methods: </strong>We performed a cross-sectional study of patients with established CAD undergoing PCI in a single tertiary center from January to December 2017. Patients were included if laboratory data required by the trial were available at local site. The inclusion and exclusion criteria were applied according to the trial protocol.</p> <p><strong>Results:</strong> A total of 802 patients underwent PCI in 2017, of whom 310 were included in the analysis. Median age was 66.5 (IQR 53.2-74.8) years, and 74.8% were male (other baseline characteristics and cardiovascular risk factors are listed in Table 1). 268 of these patients were statin treated, and 133 of these (49.6%) had low-density lipoprotein cholesterol (LDL-C) levels within the trial admitted range (>40 mg/dL and ≤100 mg/dL). After applying the trial TG inclusion criteria (≥150mg/dL and <500mg/dL), we were left with 51 patients (38.3%). Based on the trial NNT of 21, an expected two to three cardiovascular events will be avoided by treating the group of 51 patients with EPA for approximately 5 years.</p> <p><strong>Conclusions:</strong> In this real-world population with established coronary artery disease, only 50% of statin treated patients have LDL-C levels within the trial admitted range. About 40% of these are expected to benefit from EPA therapy.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site
